Plasma Methylphenidate Concentrations in Youths Treated with High-Dose Osmotic Release Oral System Formulation

Abstract

High-dose OROS MPH, used in combination with other medications, was not associated with either unusually elevated plasma MPH concentrations or with clinically meaningful changes in vital signs. Study limitations include a single time-point sampling of MPH concentrations, a small sample size, and a lack of outcome measures to address treatment effectiveness.